卒中后高血糖的管理:TEXAIS随机临床试验结果
TEXAIS是一项国际多中心2期前瞻性随机临床试验(PROBE设计),纳入急性缺血性卒中发病≤9小时的成人患者,比较艾塞那肽(5 µg每日两次皮下注射)与标准治疗5天或至出院(以较早者为准)。主要结局(意向性治疗)为卒中后7天美国国立卫生研究院卒中量表评分改善≥8分或评分0-1分的患者比例,艾塞那肽组170例中104例(61.2%)vs 标准治疗组171例中97例(56.7%)(校正比值比1.22,95%CI 0.79-1.88;P=0.38)。艾塞那肽未减少7天神经功能损害,但显著减少高血糖事件频率,无低血糖发生,且使用安全。
要点
- 艾塞那肽组7天主要结局比例61.2% vs 标准治疗组56.7%,校正比值比1.22(95%CI 0.79-1.88;P=0.38),无显著差异。
- 艾塞那肽组各四分位数患者日均高血糖频率均显著低于标准治疗组,治疗期间无低血糖事件记录。
- 轻度恶心和呕吐不良事件见于艾塞那肽组6例(3.5%)vs 标准治疗组0例(0%),无因不良事件退出。
核心结论
- 艾塞那肽治疗未减少急性缺血性卒中患者7天神经功能损害。
- 艾塞那肽显著减少高血糖事件频率,无低血糖发生,且使用安全。
- 应考虑开展使用GLP-1受体激动剂(如艾塞那肽)的更大规模急性卒中试验。
研究设计与样本
- TEXAIS试验为国际多中心2期前瞻性随机临床试验(PROBE设计),纳入急性缺血性卒中发病≤9小时的成人患者。
- 患者随机接受艾塞那肽(5 µg每日两次皮下注射)或标准治疗5天,或至出院(以较早者为准)。
- 2016年4月至2021年6月共随机350例(艾塞那肽组177例,标准治疗组173例),因COVID-19干扰和资金限制提前终止原计划招募528例。
- 中位年龄71岁(四分位距62-79),中位NIHSS评分4分(四分位距2-8)。
主要发现
- 主要结局(意向性治疗)在标准治疗组171例中97例(56.7%)vs 艾塞那肽组170例中104例(61.2%)达到(校正比值比1.22,95%CI 0.79-1.88;P=0.38)。
- 未观察到次要结局差异。
- 艾塞那肽组各四分位数患者日均高血糖频率均显著低于标准治疗组。
- 治疗期间未记录到低血糖事件。
- 轻度恶心和呕吐不良事件见于艾塞那肽组6例(3.5%)vs 标准治疗组0例(0%),无退出。
临床怎么用
- 作者认为,应考虑开展使用GLP-1受体激动剂(如艾塞那肽)的更大规模急性卒中试验。
局限性
- 原计划招募528例,因COVID-19干扰和资金限制提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hyperglycemia in acute ischemic stroke reduces the efficacy of stroke thrombolysis and thrombectomy, with worse clinical outcomes. Insulin-based therapies are difficult to implement and may cause hypoglycemia. We investigated whether exenatide, a GLP-1 (glucagon-like peptide-1) receptor agonist, would improve stroke outcomes, and control poststroke hyperglycemia with minimal hypoglycemia. METHODS: The TEXAIS trial (Treatment With Exenatide in Acute Ischemic Stroke) was an international, multicenter, phase 2 prospective randomized clinical trial (PROBE [Prospective Randomized Open Blinded End-Point] design) enrolling adult patients with acute ischemic stroke ≤9 hours of stroke onset to receive exenatide (5 µg BID subcutaneous injection) or standard care for 5 days, or until hospital discharge (whichever sooner). The primary outcome (intention to treat) was the proportion of patients with ≥8-point improvement in National Institutes of Health Stroke Scale score (or National Institutes of Health Stroke Scale scores 0-1) at 7 days poststroke. Safety outcomes included death, episodes of hyperglycemia, hypoglycemia, and adverse event. RESULTS: From April 2016 to June 2021, 350 patients were randomized (exenatide, n=177, standard care, n=173). Median age, 71 years (interquartile range, 62-79), median National Institutes of Health Stroke Scale score, 4 (interquartile range, 2-8). Planned recruitment (n=528) was stopped early due to COVID-19 disruptions and funding constraints. The primary outcome was achieved in 97 of 171 (56.7%) in the standard care group versus 104 of 170 (61.2%) in the exenatide group (adjusted odds ratio, 1.22 [95% CI, 0.79-1.88]; P=0.38). No differences in secondary outcomes were observed. The per-patient mean daily frequency of hyperglycemia was significantly less in the exenatide group across all quartiles. No episodes of hypoglycemia were recorded over the treatment period. Adverse events of mild nausea and vomiting occurred in 6 (3.5%) exenatide patients versus 0 (0%) standard care with no withdrawal. CONCLUSIONS: Treatment with exenatide did not reduce neurological impairment at 7 days in patients with acute ischemic stroke. Exenatide did significantly reduce the frequency of hyperglycemic events, without hypoglycemia, and was safe to use. Larger acute stroke trials using GLP-1 agonists such as exenatide should be considered. REGISTRATION: URL: www.australianclinicaltrials.gov.au; Unique identifier: ACTRN12617000409370. URL: https://www.clinicaltrials.gov; Unique identifier: NCT03287076.
引用
- Bladin CF, Wah Cheung N, Dewey HM, et al. Management of Poststroke Hyperglycemia: Results of the TEXAIS Randomized Clinical Trial. Stroke. 2023. PMID: 38011235. doi:10.1161/STROKEAHA.123.044568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。